Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

Oppenheimer analyst Les Sulewski has initiated coverage on Amneal Pharmaceuticals (NASDAQ: AMRX) with an Outperform rating. The firm has set a price target of $27 for the company's stock.